Phanes Therapeutics

Phanes Therapeutics is a private, pre-clinical stage biotech company pioneering the development of native IgG-like bispecific antibodies for immuno-oncology. Its core value is built upon three proprietary technology platforms—PACbody, SPECpair, and ATACCbody—designed to create bispecific antibodies with enhanced drug-like properties, manufacturability, and safety profiles, particularly for solid tumors. The company is currently in the discovery and early development phase, aiming to advance its pipeline through internal R&D and strategic collaborations to address significant unmet needs in cancer therapy.

Three proprietary platforms for bispecific antibody development: PACbody® for native IgG-like bispecifics with drug-like properties and manufacturability; SPECpair® for enhanced manufacturability of native IgG-like bispecifics; ATACCbody® for conditionally activated, conjugated IgG-like bispecifics designed to target solid tumors with minimal risk of cytokine release syndrome.

The bispecific antibody field is highly competitive, dominated by large pharma (e.g., Roche, Amgen) and established biotechs (e.g., Genmab, Regeneron) with approved drugs and advanced pipelines. Phanes differentiates by focusing on platform solutions for manufacturability and conditional activation to improve solid tumor targeting and safety.